<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C1332128" disease_type="Neoplastic Process" abbrv="">Peritoneal carcinomatosis</z:e> is regarded as a common sign of advanced <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> stage, <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e> or local recurrence of appendiceal and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and is generally associated with poor prognosis </plain></SENT>
<SENT sid="1" pm="."><plain>Although survival of patients with advanced stage <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> has markedly improved over the last 20 years with systemic treatment, comprising combination chemotherapy +/- monoclonal antibodies, the oncological outcome-especially of the subgroup of patients with <z:e sem="disease" ids="C0346989" disease_type="Neoplastic Process" abbrv="">peritoneal metastases</z:e>-is still unsatisfactory </plain></SENT>
<SENT sid="2" pm="."><plain>In addition to systemic therapy, cytoreductive surgery (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRS</z:e>) and hyperthermic intraperitoneal chemotherapy (HIPEC) are specific treatment options for a selected group of these patients and may provide an additional therapeutic benefit in the framework of an interdisciplinary treatment concept </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS/DESIGN: The COMBATAC trial is a prospective, multicenter, open-label, single-arm, single-stage phase II trial investigating perioperative systemic polychemotherapy including cetuximab in combination with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRS</z:e> and HIPEC patients with histologically proven <z:mp ids='MP_0002169'>wild-type</z:mp> KRAS colorectal or appendiceal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> and synchronous or metachronous <z:e sem="disease" ids="C1332128" disease_type="Neoplastic Process" abbrv="">peritoneal carcinomatosis</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The planned total number of patients to be recruited is 60 </plain></SENT>
<SENT sid="5" pm="."><plain>The primary endpoint is progression-free survival (PFS) </plain></SENT>
<SENT sid="6" pm="."><plain>Secondary endpoints include overall survival (OS), perioperative morbidity and treatment-associated toxicity, feasibility of the combined treatment regimen, quality of life (QoL) and histopathological regression after preoperative chemotherapy </plain></SENT>
<SENT sid="7" pm="."><plain>DISCUSSION: The COMBATAC trial is designed to evaluate the feasibility and efficacy of the combined multidisciplinary treatment regimen consisting of perioperative systemic combination chemotherapy plus cetuximab and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRS</z:e> plus bidirectional HIPEC with intraperitoneal <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01540344, EudraCT number: 2009-014040-11 </plain></SENT>
</text></document>